Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Equities researchers at HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, June 17th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings of ($0.18) per share for the quarter, up from their previous forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.55) EPS.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 59.03%. The firm had revenue of $65.00 million for the quarter, compared to analyst estimates of $54.97 million.
View Our Latest Stock Report on ESPR
Esperion Therapeutics Price Performance
Esperion Therapeutics stock opened at $1.07 on Thursday. The firm has a 50 day simple moving average of $0.96 and a 200-day simple moving average of $1.60. The stock has a market cap of $212.07 million, a price-to-earnings ratio of -1.34 and a beta of 0.67. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $3.94.
Institutional Investors Weigh In On Esperion Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp purchased a new position in shares of Esperion Therapeutics during the 1st quarter worth approximately $278,000. Graham Capital Management L.P. boosted its position in shares of Esperion Therapeutics by 153.5% during the first quarter. Graham Capital Management L.P. now owns 487,735 shares of the biopharmaceutical company’s stock worth $702,000 after buying an additional 295,320 shares during the period. State of Wyoming boosted its position in shares of Esperion Therapeutics by 93.8% during the first quarter. State of Wyoming now owns 89,936 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 43,526 shares during the period. CW Advisors LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at $74,000. Finally, Summit Financial LLC raised its holdings in shares of Esperion Therapeutics by 40.1% in the 1st quarter. Summit Financial LLC now owns 65,194 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 18,666 shares during the period. 47.39% of the stock is owned by hedge funds and other institutional investors.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Recommended Stories
- Five stocks we like better than Esperion Therapeutics
- Trading Stocks: RSI and Why it’s Useful
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Overheated Market? Analysts Watch These Red Flags
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.